Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Canton

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Infection Control and Hospital Epidemiology|March 13, 2023
Quantification of time delay between screening and subsequent initiation of contact isolation for carriers of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: A post hoc subgroup analysis of the R-GNOSIS WP5 TrialFriederike Maechler, Frank Schwab, Sonja Hansen, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2006
CTX-M: changing the face of ESBLs in EuropeDavid M Livermore, Rafael Canton, Marek Gniadkowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2023
Antimicrobial resistance level and conjugation permissiveness shape plasmid distribution in clinical enterobacteriaAida Alonso-Del Valle, Laura Toribio-Celestino, Anna Quirant, et al.
Biorxiv : the Preprint Server for Biology|June 21, 2024
Plasmid-encoded insertion sequences promote rapid adaptation in clinical enterobacteriaJorge Sastre-Dominguez, Javier DelaFuente, Laura Toribio-Celestino, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 30, 2018
Defining antimicrobial resistance in cystic fibrosisTimothy J Kidd, Rafael Canton, Miquel Ekkelenkamp, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2019
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung InfectionsValerie J Waters, Timothy J Kidd, Rafael Canton, et al.
BMJ Open|March 4, 2019
Local prevalence of extended-spectrum beta-lactamase (ESBL) producing <i>Enterobacteriaceae</i> intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in <i>Klebsiella pneumoniae</i>: a prevalence survey in a Spanish University HospitalCristina Díaz-Agero Pérez, Nieves López-Fresneña, Angela L Rincon Carlavilla, et al.
Antimicrobial Agents and Chemotherapy|August 16, 2021
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose OptimizationChristian M Gill, Elif Aktaş, Wadha Alfouzan, et al.
The Lancet. Infectious Diseases|February 23, 2020
Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trialFriederike Maechler, Frank Schwab, Sonja Hansen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 22, 2021
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosaChristian M Gill, Elif Aktaþ, Wadha Alfouzan, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Infection Control and Hospital Epidemiology|March 13, 2023
Quantification of time delay between screening and subsequent initiation of contact isolation for carriers of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: A post hoc subgroup analysis of the R-GNOSIS WP5 TrialFriederike Maechler, Frank Schwab, Sonja Hansen, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2006
CTX-M: changing the face of ESBLs in EuropeDavid M Livermore, Rafael Canton, Marek Gniadkowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2023
Antimicrobial resistance level and conjugation permissiveness shape plasmid distribution in clinical enterobacteriaAida Alonso-Del Valle, Laura Toribio-Celestino, Anna Quirant, et al.
Biorxiv : the Preprint Server for Biology|June 21, 2024
Plasmid-encoded insertion sequences promote rapid adaptation in clinical enterobacteriaJorge Sastre-Dominguez, Javier DelaFuente, Laura Toribio-Celestino, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 30, 2018
Defining antimicrobial resistance in cystic fibrosisTimothy J Kidd, Rafael Canton, Miquel Ekkelenkamp, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2019
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung InfectionsValerie J Waters, Timothy J Kidd, Rafael Canton, et al.
BMJ Open|March 4, 2019
Local prevalence of extended-spectrum beta-lactamase (ESBL) producing <i>Enterobacteriaceae</i> intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in <i>Klebsiella pneumoniae</i>: a prevalence survey in a Spanish University HospitalCristina Díaz-Agero Pérez, Nieves López-Fresneña, Angela L Rincon Carlavilla, et al.
Antimicrobial Agents and Chemotherapy|August 16, 2021
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose OptimizationChristian M Gill, Elif Aktaş, Wadha Alfouzan, et al.
The Lancet. Infectious Diseases|February 23, 2020
Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trialFriederike Maechler, Frank Schwab, Sonja Hansen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 22, 2021
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosaChristian M Gill, Elif Aktaþ, Wadha Alfouzan, et al.
Pageof 4